Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Pathology|March 18, 2025
Molecular testing of lung cancer in Australia: consensus best practice recommendations from the Royal College of Pathologists of Australasia in collaboration with the Thoracic Oncology Group of AustralasiaWendy A Cooper, Benhur Amanuel, Caroline Cooper, et al.
Neuro-Oncology|May 13, 2021
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU studyHao-Wen Sim, Kerrie L McDonald, Zarnie Lwin, et al.
BMJ Open|September 14, 2022
Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastomaBenjamin Y Kong, Hao-Wen Sim, Elizabeth H Barnes, et al.
Cancer|August 14, 2025
Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohortSun Young Rha, Eduardo Castanon, Sanjeev Gill, et al.
BMJ Supportive & Palliative Care|February 22, 2023
Acetazolamide versus placebo for cerebral oedema requiring dexamethasone in recurrent and/or progressive high-grade glioma: phase II randomised placebo-controlled double-blind studyMeera R Agar, Anna K Nowak, Elizabeth J Hovey, et al.
Neuro-Oncology|October 28, 2017
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastomaHui K Gan, David A Reardon, Andrew B Lassman, et al.
Neuro-Oncology Practice|October 13, 2025
Clinical outcomes and management of CDKN2A/B homozygously deleted IDH-mutant astrocytomas-a cohort study and patterns of care surveyAlexander Yuile, Laveniya Satgunaseelan, Kimberley L Alexander, et al.
Neuro-Oncology|July 9, 2018
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trialAndrew B Lassman, Martin J van den Bent, Hui K Gan, et al.
Cancer Chemotherapy and Pharmacology|October 28, 2017
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international studyMartin van den Bent, Hui K Gan, Andrew B Lassman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2026
A Phase 1 and Biodistribution study of Ifabotuzumab, a humanized agonistic EphA3-targeted antibody, in patients with recurrent glioblastomaHui K Gan, Lawrence Cher, Po-Ling Inglis, et al.
Pageof 8